RECRUITING

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

Official Title

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

Quick Facts

Study Start:2023-04-30
Study Completion:2025-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05843552

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age between 18-80yrs
  2. * Restricted to participants who are untreated, obligate carriers and healthy controls.
  3. * Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.
  1. * Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
  2. * Exclude participants who are currently on therapy for their GD
  3. * Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.

Contacts and Locations

Study Contact

Reena Kartha, PhD, MS
CONTACT
612-626-2436
rvkartha@umn.edu
Marcia Terluk, PhD
CONTACT
612-625-7972
mrterluk@umn.edu

Principal Investigator

Reena Kartha, PhD, MS
PRINCIPAL_INVESTIGATOR
University of Minnesota
Subbaya Subramanian, PhD, MS
PRINCIPAL_INVESTIGATOR
University of Minnesota

Study Locations (Sites)

University of Minnesota
Minneapolis, Minnesota, 55414
United States

Collaborators and Investigators

Sponsor: University of Minnesota

  • Reena Kartha, PhD, MS, PRINCIPAL_INVESTIGATOR, University of Minnesota
  • Subbaya Subramanian, PhD, MS, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-30
Study Completion Date2025-05

Study Record Updates

Study Start Date2023-04-30
Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

  • Gaucher Disease